Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial - Concepedia

Concepedia

Publication | Open Access

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

DOI Full Paper Access

392

Citations

17

References

2021

Year

Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Carmelo Carlo‐Stella, Fritz Offner, Anna Sureda, Gilles Salles, Joaquín Martínez‐López, Michael Crump, Denise Thomas,

Journal of Clinical Oncology

Abstract

In patients with predominantly refractory, aggressive B-NHL, glofitamab showed favorable activity with frequent and durable CRs and a predictable and manageable safety profile.

References

	Year	Citations

Page 1